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ABSTRACT
Introduction: The optimal stage for dipeptidyl
peptidase-4 (DPP-4) inhibitor therapy in the
course of type 2 diabetes mellitus (T2DM) is still
under discussion, with often a perception that
treatment with these agents may be less
beneficial with increasing disease progression,
due to loss of beta-cell function, and with
increasing insulin resistance (IR), where beta-
cell function is less prominent. This work,
therefore, aimed to assess the impact of such
factors on the efficacy of the DPP-4 inhibitor,
vildagliptin, in add-on therapy to metformin.
Methods: A pooled analysis of 24-week efficacy
data of vildagliptin 50 mg twice daily (b.i.d.)
(n = 2,478) from four add-on to metformin
studies was performed. Analyses for changes
in hemoglobin A1c (HbA1c) were stratified
according to baseline IR stage (homeostasis
model assessment [Homa IR]\5, C5), body
mass index (BMI) (\27, C27 to\30, C30 kg/m2),
T2DM duration (0 to\1, C1 to\5, C5 years),
and duration of metformin use (0 to\1, C1 to
\5, C5 years). Data from patients treated with
sulfonylureas (SUs) (n = 2,010) in the pooled
studies are provided as reference.
Results: Patients in the vildagliptin and SU
groups had mean age, HbA1c, BMI, Homa IR,
duration of T2DM and metformin use of 58 years,
7.7%, 32 kg/m2, 4.3, 5.9 years and 3.0 years,
respectively. Reductions from baseline in HbA1c
with vildagliptin were very similar across
Homa IR (mean 2.8 and 8.6), BMI (mean 24.9,
28.5, and 35.3 kg/m2), T2DM duration (mean 0.6,
2.9, and 9.7 years), and duration of metformin use
(mean 0.6, 2.6, and 7.9 years) categories, showing
significant drops in HbA1c of approximately
-0.7% (baseline 7.7%). The results in patients
receiving SUs were comparable to those seen in
the vildagliptin group.
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Conclusion: Vildagliptin add-on therapy to
metformin was efficacious independent of IR
stage and BMI, as well as disease duration and
duration of prior metformin use, indicating
that, contrary to a not uncommon perception,
more obese patients and patients with long-
standing T2DM can benefit from treatment
with the DPP-4 inhibitor, vildagliptin.
Keywords: Body mass index; Dipeptidyl
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive
disease, with increasing insulin resistance (IR)
(tied to obesity and/or adiposity) and
deteriorating beta-cell function being key
pathophysiologic defects in the development
and worsening of hyperglycemia.
Based on the understanding of the
pathogenesis of T2DM, several distinct
pharmacological therapies have been
developed. Within this armamentarium,
dipeptidyl peptidase-4 (DPP-4) inhibitors are
the most recent addition to the oral treatment
options available in clinical practice for the
treatment of T2DM.
The DPP-4 enzyme rapidly inactivates the
incretin hormones, glucagon-like peptide-1
(GLP-1) and gastric inhibitory polypeptide
(GIP) [1], which play a crucial role in glucose
homeostasis [2, 3]. DPP-4 inhibitors bind to
the catalytic site of DPP-4, resulting in
prolonged inhibition of the enzyme, thus,
raising levels of intact GLP-1 and GIP [4]. The
resulting improvement in islet dysfunction is
a key mechanism underlying the glucose-
lowering mechanism of DPP-4 inhibitors [4].
There is also a potential beta-cell preservation
effect, as judged from rodent models, in which
an increase in beta-cell mass through stimulation
of neogenesis and proliferation, as well as an
inhibition of apoptosis, has been seen with
GLP-1/DPP-4 inhibitors [5, 6].
While DPP-4 inhibitor therapy has been
studied in a variety of clinical study settings
[7–10], the optimal stage for their use in the
course of T2DM is still under debate. Based on
the known effects on beta-cell function, there is
frequently a perception that treatment with
these agents may be less efficacious with
increasing disease progression, due to loss of
beta-cell function, and with increasing IR,
where beta-cell function is proportionally less
important.
The present paper, therefore, aimed to
evaluate the impact of such factors (i.e., T2DM
duration and duration of previous therapy, and
IR and body mass index [BMI]) on the efficacy of
the DPP-4 inhibitor, vildagliptin, using a pooled
database of studies in add-on therapy to
metformin. Vildagliptin is a DPP-4 inhibitor
that has been extensively studied in a large
clinical program, with proven efficacy and a
well-established safety profile [8, 11–14]. The
present paper reports the results of these new
pooled subgroup analyses with vildagliptin.
METHODS
Populations
The efficacy analyses included all randomized,
double-blind, controlled, parallel-group add-on
to metformin studies with vildagliptin 50 mg
twice daily (b.i.d.) (the highest approved
and most commonly used dose of the drug). A
total of four studies were pooled (termed
‘pooled add-on to metformin population’).
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The efficacy population comprised all patients
who were included in the respective primary
efficacy populations of the individual studies
[15–18]. Data collected in the first 24 weeks of
treatment from these studies were included in
the analyses. Details of the study designs are
summarized in Appendix Table 3 and the
individual study publications [15–18].
Assessments
Hemoglobin A1c (HbA1c) was measured regularly
in all studies. The laboratory assessments were
performed by central laboratories: Bioanalytical
Research Corporation-EU (Ghent, Belgium),
Diabetes Diagnostics Laboratory (Columbia,
MO, US), and Covance (Geneva, Switzerland,
Singapore, or Indianapolis, IN, US).
Homeostasis model assessment IR (Homa IR)
was calculated based on the following formula:
Homa IR = (fasting insulin [lU/mL]) 9 (fasting
glucose [mmol/L])/22.5. Glomerular filtration
rate (GFR) was estimated by the Modification of
Diet in Renal Disease study method (MDRD) [19].
Data Analysis
The total number of patients, and demography
and baseline characteristics were recorded.
Efficacy analyses were stratified according to
baseline IR stage (Homa IR\5 and C5), BMI
(\27, C27 to\30, C30 kg/m2), T2DM duration
(0 to\1, C1 to\5, C5 years), and duration of
metformin use (0 to\1, C1 to\5, C5 years).
Mean changes from baseline in HbA1c at the
week 24 endpoint in the defined subgroups
were analyzed using last observation carried
forward (LOCF). Within-group comparisons
(endpoint vs. baseline) were made using one-
sample t test at a significance level of 0.05.
Efficacy data are reported for vildagliptin
50 mg b.i.d. (n = 2,478), with data from patients
treated with a sulfonylurea (SU) in the pooled
studies being provided as reference (n = 2,010).
While the SU group had a comparable number
of patients to the vildagliptin group, the two
other comparator groups in the studies (placebo
and thiazolidinedione [TZD]) comprised only
2.6% and 5.7%, respectively, of patients in the
pooled population; thus, not representing
meaningful reference groups to be analyzed.
Ethics and Good Clinical Practice
All study participants provided written
informed consent. All protocols were approved
by the independent ethics committee/
institutional review board at each study site or
country. All studies were conducted using good




Table 1 summarizes the demographic and
baseline characteristics of patients in the
pooled add-on to metformin population. The
population studied was representative of a broad
spectrum of T2DM patients, with a mean age of
58 years, mean HbA1c of 7.7%, mean fasting
blood glucose (FPG) of 9.6 mmol/L, mean BMI
of 32 kg/m2, and mean Homa IR of 4.3,
respectively. The mean duration of diagnosed
T2DM was 5.9 years, with a mean duration of
metformin use of 3.0 years. Approximately 30%
of patients had renal impairment (mostly
mild),[65% had hypertension, and about 50%
had dyslipidemia. The majority of patients
([80%) were Caucasian. The demographic and
baseline characteristics were comparable across
the vildagliptin group and the SU reference
group.
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Efficacy by Subgroups
Table 2 displays mean changes from baseline to
week 24 in HbA1c with vildagliptin 50 mg b.i.d.
according to Homa IR, BMI, T2DM duration,
and duration of metformin use in the pooled
add-on to metformin population.
The influence of IR on the efficacy of
vildagliptin was assessed by stratification
according to two baseline Homa IR categories,
Homa IR\5 (mean = 2.8) and Homa IR C5
(mean = 8.6). In addition, three BMI categories
were analyzed, BMI\27 kg/m2 (mean = 24.9 kg/m2),
C27 to\30 kg/m2 (mean = 28.5 kg/m2), and
C30 kg/m2 (mean = 35.3 kg/m2). HbA1c was
reduced to a very similar extent independent
of baseline Homa IR or BMI category. For
example, HbA1c (± SE) was reduced by -0.67 ±
0.04% (baseline 7.80 ± 0.05%), -0.67 ± 0.04%
(baseline 7.74 ± 0.04%), and -0.63 ± 0.02%
(baseline 7.72 ± 0.03%) in the BMI subgroups
of\27, C27 to\30, and C27 kg/m2, respectively.
Table 1 Demography and baseline characteristics (pooled







Age (years) 57.5 ± 9.4 58.0 ± 9.5
C65 638 (25.7) 595 (29.6)
Sex
Male 1,347 (54.4) 1,070 (53.2)
Female 1,131 (45.6) 940 (46.8)
Race
Caucasian 2,089 (84.3) 1,691 (84.1)
Black 43 (1.7) 25 (1.2)
Asian 103 (4.2) 86 (4.3)
Hispanic/Latino 227 (9.2) 190 (9.5)
All other 16 (0.6) 18 (0.9)
n 2,477 2,010
HbA1c (%) 7.7 ± 1.0 7.6 ± 0.9
n 2,475 2,009
FPG (mmol/L) 9.7 ± 2.5 9.5 ± 2.5
n 2,472 2,003
BMI (kg/m2) 31.9 ± 5.3 31.5 ± 5.2
B27 465 (18.8) 421 (20.9)
B30 1,022 (41.2) 878 (43.7)
[30 1,450 (58.5) 1,125 (56.0)
[35 651 (26.3) 468 (23.3)
Not recorded 6 (0.2) 7 (0.3)
n 2,121 1,703
Homa IR 4.4 ± 4.2 4.2 ± 3.7
\5 1,519 (61.3) 1,267 (63.0)
C5 602 (24.3) 436 (21.7)




5.9 ± 5.1 6.0 ± 5.1
0 to\1 237 (9.6) 202 (10.0)
C1 to\5 1,079 (43.5) 850 (42.3)





3.0 ± 3.0 3.0 ± 2.9
0 to\1 713 (28.8) 591 (29.4)
C1 to\5 1,294 (52.2) 1,047 (52.1)
C5 470 (19.0) 372 (18.5)












Normal 1,713 (69.1) 1,367 (68.0)
Mild (C50, B80) 739 (29.8) 626 (31.1)
Moderate
(C30, B50)
23 (0.9) 17 (0.8)
Severe (\30) 2 (0.1) 0 (0.0)
Not recorded 1 (0.0) 0 (0.0)
Hypertension 1,586 (64.0) 1,375 (68.4)
Dyslipidemia 1,279 (51.6) 992 (49.4)
b.i.d. twice daily, BMI body mass index, FPG fasting plasma
glucose, GFR glomerular ﬁltration rate, HbA1c hemoglobin A1c,
Homa IR homeostasis model assessment insulin resistance,
MDRD Modiﬁcation of Diet in Renal Disease, SU
sulfonylurea, T2DM type 2 diabetes mellitus, Vilda vildagliptin
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The impact of disease progression on the
efficacy of vildagliptin was evaluated by
stratification according to three T2DM duration
categories, 0 to\1 year (mean = 0.6 years),
C1 to\5 years (mean = 2.9 years), and C5 years
(mean = 9.7 years). In addition, the duration of
Table 2 Efﬁcacy (HbA1c [%]) by Homa IR, BMI, T2DM duration and duration of metformin use
Vilda 50 mg b.i.d.1 metformin SU1 metformin
BL Mean D BL Mean D
BL Homa IR
n 1,507 1,237
\5 (mean = 2.8/2.7) 7.63 ± 0.02 -0.65 ± 0.02* 7.51 ± 0.03 -0.76 ± 0.02*
n 598 428
C5 (mean = 8.6/8.3) 8.07 ± 0.05 -0.68 ± 0.04* 7.80 ± 0.05 -0.77 ± 0.05*
BL BMI
n 444 398
\27 kg/m2 (mean = 24.9/25.1) 7.80 ± 0.05 -0.67 ± 0.04* 7.66 ± 0.05 -0.80 ± 0.04*
n 556 453
C27 to\30 kg/m2 (mean = 28.5/28.4) 7.74 ± 0.04 -0.67 ± 0.04* 7.59 ± 0.04 -0.79 ± 0.04*
n 1,446 1,106
C30 kg/m2 (mean = 35.3/35.1) 7.72 ± 0.03 -0.63 ± 0.02* 7.58 ± 0.03 -0.73 ± 0.03*
BL T2DM duration
n 236 198
0 to\1 year (mean = 0.6/0.6) 7.47 ± 0.06 -0.64 ± 0.05* 7.32 ± 0.06 -0.73 ± 0.06*
n 1,061 829
C1 to\5 years (mean = 2.9/2.9) 7.65 ± 0.03 -0.60 ± 0.03* 7.49 ± 0.03 -0.71 ± 0.03*
n 1,155 936
C5 years (mean = 9.7/9.8) 7.88 ± 0.03 -0.69 ± 0.03* 7.75 ± 0.03 -0.80 ± 0.03*
BL duration of metformin use
n 709 580
0 to\1 year (mean = 0.6/0.6) 7.70 ± 0.04 -0.63 ± 0.03* 7.53 ± 0.04 -0.75 ± 0.04*
n 1,274 1,022
C1 to\5 years (mean = 2.6/2.6) 7.70 ± 0.03 -0.63 ± 0.02* 7.58 ± 0.03 -0.74 ± 0.03*
n 468 361
C5 years (mean = 7.9/7.7) 7.93 ± 0.05 -0.70 ± 0.04* 7.76 ± 0.05 -0.82 ± 0.05*
Data are mean ± SE
b.i.d. twice daily, BL baseline, BMI body mass index, HbA1c hemoglobin A1c, Mean D mean change from BL, n number of
patients with observations at both baseline and endpoint, SU sulfonylurea, T2DM type 2 diabetes mellitus, Vilda
vildagliptin
* P\0.0001
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metformin use was considered, with categories of
0 to\1 year (mean = 0.6 years), C1 to \5 years
(mean = 2.6 years), and C5 years (mean =
7.9 years). Patients with shorter and longer
duration of T2DM and metformin use had very
similar decreases in HbA1c. For example, HbA1c
(±SE) was reduced by -0.64 ± 0.05% (baseline
7.47 ± 0.06%), -0.60 ± 0.03% (baseline 7.65 ±
0.03%), and -0.69 ± 0.03% (baseline 7.88 ±
0.03%) in the T2DM duration subgroups of
0 to\1, C1 to\5, and C5 years, respectively.
Table 2 also displays efficacy results in the
different sub-categories for the SU reference
group. The results in patients receiving a SU
were comparable to those seen in the
vildagliptin group, with similar HbA1c
reductions across the different Homa IR, BMI,
T2DM duration, and duration of metformin use
subgroups.
DISCUSSION
The present paper evaluated the impact of IR,
BMI, disease duration, and duration of
metformin use on the efficacy of vildagliptin
in patients with T2DM treated with metformin.
The pooled analysis found similar efficacy of
vildagliptin independent of these factors,
indicating that patients with higher IR, more
obese patients, and patients with long-standing
T2DM can benefit from treatment with the
DPP-4 inhibitor, vildagliptin, in combination
with metformin.
These data can provide relevant information
for the use of vildagliptin in clinical practice, in
particular given the not uncommon perception
that treatment with DPP-4 inhibitors may be
less beneficial with increasing disease
progression, due to loss of beta-cell function,
and with increasing IR, where beta-cell function
is proportionally less important. The notion of
DPP-4 inhibitors being more beneficial in
patients with shorter disease duration may at
least be in part related to the promise from
animal models [5, 6] that these incretin-based
therapies may be able to interfere with disease
progression if used as an early intervention,
when sufficient beta-cell function/mass can be
still be preserved or restored, which raised
particular attention when these drugs initially
became available. On the other hand,
consistent with the findings of the present
report, vildagliptin has meanwhile been
shown to be efficacious across a wide disease
spectrum, including add-on therapy to insulin
as well as patients with renal impairment,
both involving patients with long-standing
T2DM (mean T2DM duration 13–17 years)
[20–23].
In this context, it is important to keep in
mind that vildagliptin, in addition to
improving beta-cell function, also enhances
alpha-cell function (i.e., suppresses inappropriate
glucagon secretion as shown after oral glucose
and meal ingestion [24–26]), with the changes
in islet hormone (i.e., increased insulin and
reduced glucagon) secretion leading to a
profound effect to suppress hepatic glucose
production [27]. Furthermore, vildagliptin is
associated with reduced insulin resistance due
to reduced lipotoxicity [28, 29]. Thus, a variety
of pancreatic and extra-pancreatic effects are
active to support the efficacy of vildagliptin [4].
Similar results to those seen with vildagliptin
plus metformin were also seen in the group of
patients treated with SUs in combination with
metformin, who were analyzed as a reference
group. The common perception is that both
DPP-4 inhibitors and SUs tend to be more
efficacious in lean than obese individuals and
the reverse is true for TZDs. The data in this
study do not support this perception about
vildagliptin and SUs, and the authors are
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unaware of any data that does. In contrast,
addition of the TZD, rosiglitazone, to
metformin was indeed shown to be most
efficacious in obese, insulin-resistant patients,
as expected from the mechanism of action [30].
Similar results were also seen with pioglitazone
added to SU therapy in a small Japanese study;
HbA1c was decreased considerably more in
the Homa IR C4 category compared to the
\4 subgroup [31]. The current study does not
address the question of whether a longer
duration of SU use is associated with a reduced
response, but indicates that addition of SUs to
patients with a longer duration of T2DM is not
associated with reduced efficacy. This is in
contrast to one open-label study of glimepiride
monotherapy [32], which showed a weak
association of longer duration of diabetes with
the likelihood of being a nonresponder (odds
ratio [OR] = 1.096); however, the study was
confounded by a strong correlation with
previous oral antidiabetic drug (OAD)
treatment (OR = 2.506).
In light of the applicability of the reported
results, it is important to note that each of the
categories investigated included a broad range
of vildagliptin-treated patients, with means of
IR categories from 2.8 to 8.6, of BMI from
24.9 to 35.3 kg/m2, and of disease duration
from\1 year to nearly 10 years (overall range
0.1–40.1 years). Another important factor for
the interpretation of the subgroup results
is that HbA1c levels were well matched
between the different categories, which is
an important consideration given that
HbA1c levels strongly influence response to
treatment. Since metformin was used as a
background drug, some limitations of the
clinical applicability of the present results to
other indications cannot be ruled out, and it
will be of interest to investigate whether
similar results will be seen with vildagliptin
in combination with other drugs, as well as
in monotherapy. While no such data are
currently available for the subgroups of disease
duration or IR stage, in a study with vildagliptin
monotherapy in patients with mild
hyperglycemia, the same treatment effect was
seen in patients with baseline BMI\30
and C30 kg/m2 [33].
CONCLUSION
Taken together, the present pooled analysis
provides a comprehensive assessment of the
efficacy of vildagliptin in subgroups of IR stage
and BMI, as well as disease duration and
duration of prior metformin use, showing
similar efficacy of vildagliptin across a wide
spectrum of these categories.
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